Journal of cutaneous medicine and surgery · 2001
Epidermolysis bullosa acquisita responsive to dapsone therapy.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hughes A P, Callen J P
Аннотация
BACKGROUND: Epidermolysis bullosa acquisita (EBA) is a chronic subepidermal blistering disease that is frequently resistant to therapy.
OBJECTIVE: A 58-year-old man who had a one-year history of a bullous eruption involving the hands, forearms, trunk, scalp, and oral mucosa. Histopathology revealed a subepidermal bulla, and direct and indirect immunofluorescence studies were consistent with EBA. The patient failed respond to niacinamide and tetracycline and oral prednisone 40 mg per day.
METHODS: Complete control of his blistering was achieved within two months of initiating oral dapsone, 150 mg per day.
CONCLUSION: Dapsone may be an effective agent for some patients with EBA.
OBJECTIVE: A 58-year-old man who had a one-year history of a bullous eruption involving the hands, forearms, trunk, scalp, and oral mucosa. Histopathology revealed a subepidermal bulla, and direct and indirect immunofluorescence studies were consistent with EBA. The patient failed respond to niacinamide and tetracycline and oral prednisone 40 mg per day.
METHODS: Complete control of his blistering was achieved within two months of initiating oral dapsone, 150 mg per day.
CONCLUSION: Dapsone may be an effective agent for some patients with EBA.